Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 855-867

  Buoncervello, Maria ^a   Borghi, Paola ^a   Romagnoli, Giulia ^a   Spadaro, Francesca ^a   Belardelli, Filippo ^a   Toschi, Elena ^a   Gabriele, Lucia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; APICIDIN; CALRETICULIN; CASPASE 8; DOCETAXEL; HIGH MOBILITY GROUP B1 PROTEIN; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; PROCASPASE 8; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR CTCF;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84866528637     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121020     Document Type: Article

References (64)

1. Jia J, Zhu F, Ma X, Cao Z, Li Y, and Chen YZ (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8, 111-128.
2. Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, and Clarke R (2011). Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 11, 523-532.
3. Higgins MJ and Baselga J (2011). Targeted therapies for breast cancer. J Clin Invest 121, 3797-3803.
4. Luu T, Chung C, and Somlo G (2011). Combining emerging agents in advanced breast cancer. Oncologist 16, 760-771.
5. Gines J, Sabater E, Martorell C, Grau M, Monroy M, and Casado MA (2011). Efficacy of taxanes as adjuvant treatment of breast cancer: a review and metaanalysis of randomised clinical trials. Clin Transl Oncol 13, 485-498.
6. Thomas S and Munster PN (2009). Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280, 184-191.
7. Noh JH, Song JH, Eun JW, Kim JK, Jung KH, Bae HJ, Xie HJ, Ryu JC, Ahn YM, Wee SJ, et al. (2009). Systemic cell-cycle suppression by apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. Int J Mol Med 24, 205-226.
8. Park H, Im JY, Kim J, Choi WS, and Kim HS (2008). Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-rastransformed breast epithelial cells. Int J Mol Med 21, 325-333.
9. Im JY, Park H, Kang KW, Choi WS, and Kim HS (2008). Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and -negative human breast cancer cells. Chem Biol Interact 172, 235-244.
10. Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, Shridhar V, Sanderson SO, and Roberts LR (2009). Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol 50, 1112-1121.
11. Jones P, Altamura S, De Francesco R, Paz OG, Kinzel O, Mesiti G, Monteagudo E, Pescatore G, Rowley M, Verdirame M, et al. (2008). A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem 51, 2350-2353.
12. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, and Chen YT (2002). Cancer/ testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188, 22-32.
13. Kang Y, Hong JA, Chen GA, Nguyen DM, and Schrump DS (2007). Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 26, 4394-4403.
14. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, et al. (2005). Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65, 7763-7774.
15. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H III, Schrump DS, et al. (2005). Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65, 7751-7762.
16. D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al. (2008). BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98, 571-579.
17. D'Arcy V, Abdullaev ZK, Pore N, Docquier F, Torrano V, Chernukhin I, Smart M, Farrar D, Metodiev M, Fernandez N, et al. (2006). The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 12, 5978-5986.
18. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, and Agadjanyan MG (2007). Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 178, 566-573.
19. Wong ST and Goodin S (2009). Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 29, 954-965.
20. Grimm D, Wehland M, Pietsch J, Infanger M, and Bauer J (2011). Drugs interfering with apoptosis in breast cancer. Curr Pharm Des 17, 272-283.
21. Labi V, Grespi F, Baumgartner F, and Villunger A (2008). Targeting the Bcl-2- regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 15, 977-987.
22. Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesniere A, Ghiringhelli F, Apetoh L, Morel Y, et al. (2010). Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 1209, 99-108.
23. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, and Agostinis P (2010). Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805, 53-71.
24. Pisetsky DS, Gauley J, and Ullal AJ (2011). HMGB1 and microparticles as mediators of the immune response to cell death. Antioxid Redox Signal 15, 2209-2219.
25. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, and Oppenheim JJ (2007). High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81, 59-66.
26. Bachmeier BE, Albini A, Vene R, Benelli R, Noonan D, Weigert C, Weiler C, Lichtinghagen R, Jochum M, and Nerlich AG (2005). Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res 305, 83-98.
27. Bayet-Robert M, Morvan D, Chollet P, and Barthomeuf C (2010). Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat 120, 613-626.
28. Hines WC, Bazarov AV, Mukhopadhyay R, and Yaswen P (2010). BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One 5, e9738.
29. Liu QJ and Gao B (2008). Manipulation of MHC-I/TCR interaction for immune therapy. Cell Mol Immunol 5, 171-182.
30. Torabi-Rahvar M, Bozorgmehr M, Jeddi-Tehrani M, and Zarnani AH (2011). Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discov Today 16, 733-740.
31. Levitzki A and Klein S (2010). Signal transduction therapy of cancer. Mol Aspects Med 31, 287-329.
32. Thurn KT, Thomas S, Moore A, and Munster PN (2011). Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7, 263-283.
33. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, and Chandra J (2011). Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011, 514261.
34. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al. (2011). A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104, 1828-1835.
35. Linares A, Dalenc F, Balaguer P, Boulle N, and Cavailles V (2011). Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol 2011, 856985.
36. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, and Kim CS (2011). A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL). Invest New Drugs 30, 1434-1442.
37. Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, and Kim CS (2010). Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol 184, 2557-2564.
38. de Necochea-Campion R, Ghochikyan A, Josephs SF, Zacharias S, Woods E, Karimi-Busheri F, Alexandrescu DT, Chen CS, Agadjanyan MG, and Carrier E (2011). Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med 9, 213.
39. Yoon SL, Kim DC, Cho SH, Lee SY, Chu IS, Heo J, and Leem SH (2010). Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS. BMB Rep 43, 698-703.
40. Martin-Kleiner I (2012). BORIS in human cancers-a review. Eur J Cancer 48, 929-935.
41. Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, et al. (2009). Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 4, e4961.
42. Geldmacher A, Freier A, Losch FO, and Walden P (2011). Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses. Hum Vaccin 7(suppl), 115-119.
43. Akers SN, Odunsi K, and Karpf AR (2010). Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6, 717-732.
44. Caballero OL and Chen YT (2009). Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100, 2014-2021.
45. Bao L, Dunham K, and Lucas K (2011). MAGE-A1, MAGE-A3, and NYESO- 1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 60, 1299-1307.
46. Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, and Liu LF (2012). Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 7, e32542.
47. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, and Maio M (2007). Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 13, 3333-3338.
48. Woan KV, Sahakian E, Sotomayor EM, Seto E, and Villagra A (2012). Modulation of antigen-presenting cells by inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 90, 55-65.
49. John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, and Pandha H (2010). Differential effects of paclitaxel on dendritic cell function. BMC Immunol 11, 14.
50. Shurin GV, Tourkova IL, Kaneno R, and Shurin MR (2009). Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183, 137-144.
51. Tanaka H, Matsushima H, Nishibu A, Clausen BE, and Takashima A (2009). Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69, 6987-6994.
52. Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, and Armstrong TD (2010). Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 263, 79-87.
53. Montero A, Fossella F, Hortobagyi G, and Valero V (2005). Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6, 229-239.
54. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. (2010). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 71, 768-778.
55. Haynes NM, van der Most RG, Lake RA, and Smyth MJ (2008). Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 20, 545-557.
56. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28, 578-590.
57. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, and Kroemer G (2011). Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30, 61-69.
58. Tang D, Loze MT, Zeh HJ, and Kang R (2010). The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 6, 1181-1183.
59. Andersson U and Tracey KJ (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29, 139-162.
60. Tang D, Kang R, Zeh HJ III, and Lotze MT (2010). High-mobility group box 1 and cancer. Biochim Biophys Acta 1799, 131-140.
61. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, et al. (2007). High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30, 596-606.
62. Huang B, Sikorski R, Kirn DH, and Thorne SH (2011). Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 18, 164-172.
63. Zhuang W, Qin Z, and Liang Z (2009). The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 41, 341-351.
64. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, Klune JR, Zlotnicki J, Billiar T, and Tsung A (2010). High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285, 39888-39897.